Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had ...
Abstract. MTAP deletions occur in 10-15% of all human cancers, providing one of the largest precision oncology patient populations. MTA-cooperative PRMT5 inhibitors leverage the well-characterized ...
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
Background: LIV-1, also known as SLC39A6 or ZIP6, is a transmembrane protein belonging to the zinc transporter family. LIV-1 is a promising target for antibody-drug conjugate (ADC) therapy due to its ...
You do not currently have access to this content.
Cancer Res (2023) 83 (7_Supplement): 1143.
Spencer Mirabile-Brightman, Bjoern Peters, Himangshu Sonowal, Zachary Berman, Zev Wainberg, Aaron Miller, Karen Messer, Jiayu Chen, Yago Pico de Coana, Peter Ellmark, Stephen Schoenberger, Rebekah R.
Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a ...
Tertiary lymphoid structures (TLS) are organized immune cell aggregates that assemble within tumors and function as local antitumor immune hubs. Although TLSs have emerged as promising biomarkers of ...
Cancer Res (2025) 85 (8_Supplement_2): CT221. Patients with stage II colon cancer not classified as high risk (pT4 microsatellite stable) do not receive adjuvant chemotherapy (ACT) according to Dutch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results